Xgeva (Denosumab) Dosing
Xgeva is dosed at 120 mg subcutaneously every 4 weeks for prevention of skeletal-related events in patients with bone metastases from solid tumors or multiple myeloma, with mandatory calcium and vitamin D supplementation. 1
Standard Dosing Regimen
Bone Metastases from Solid Tumors and Multiple Myeloma
- Dose: 120 mg subcutaneously 1
- Frequency: Every 4 weeks 2, 3
- Route: Subcutaneous injection in upper arm, upper thigh, or abdomen 1
- Loading dose: Not required for bone metastases 1
- Duration: Continue until substantial decline in performance status 2
Giant Cell Tumor of Bone and Hypercalcemia of Malignancy
- Dose: 120 mg subcutaneously every 4 weeks 1
- Loading doses: Additional 120 mg doses on Days 8 and 15 of the first month 1
Dosing Interval Considerations
Denosumab must be administered every 4 weeks and cannot be safely extended to longer intervals. 3 Unlike zoledronic acid, which can be de-escalated to every 12 weeks after initial monthly treatment 4, 3, extending denosumab intervals beyond 4 weeks is not currently recommended due to lack of supporting data 2, 3.
This distinction is critical: while NCCN and ESMO guidelines support every-12-week dosing for zoledronic acid based on noninferiority trials 2, 4, no such evidence exists for denosumab 2, 3.
Renal Dose Adjustments
No dose adjustment is required for renal impairment, making denosumab particularly advantageous in patients with severe kidney disease. 5, 3, 6
- CrCl >30 mL/min: No adjustment needed 1, 7
- CrCl <30 mL/min or dialysis: No dose adjustment required, but denosumab is preferred over bisphosphonates 5, 3
- Severe renal impairment: Denosumab is the agent of choice when aminobisphosphonates are contraindicated 5, 3
Critical Caveat for Renal Impairment
Patients with severe renal dysfunction (CrCl <30 mL/min) have significantly higher risk of severe hypocalcemia 5, 7, 8. Enhanced monitoring and aggressive calcium/vitamin D supplementation are mandatory in this population 7, 8, 9.
Calcium and Vitamin D Supplementation
Calcium and vitamin D supplementation is mandatory when administering denosumab—this is not optional. 2, 5
Recommended Supplementation
- Calcium: 1,200-1,500 mg daily 2
- Vitamin D: 400-800 IU daily (vitamin D3) 2
- Timing: Must be corrected before initiating therapy and continued throughout treatment 3, 1
Hypocalcemia Monitoring
- Pre-existing hypocalcemia must be corrected before starting denosumab 1
- Monitor calcium levels closely, especially in the first weeks of therapy 1, 8
- Serum calcium typically reaches nadir at 1-3 months, with more pronounced decreases in CKD patients (6.48% vs 3.42% decline) 8
- Seven patients in one study had nadir calcium <7.5 mg/dL, with 4 having advanced renal disease 7
- No patient who received adequate calcium and vitamin D supplementation became hypocalcemic in the renal impairment study 7
Administration Details
Preparation
- Visually inspect for particulate matter and discoloration 1
- May contain trace amounts of translucent to white proteinaceous particles (normal) 1
- Allow to reach room temperature (15-30 minutes) before administration 1
- Do not warm by any other method 1
Injection Technique
- Use 27-gauge needle 1
- Inject entire contents of vial 1
- Single-dose vial—discard after use 1
- Do not administer intravenously, intramuscularly, or intradermally 1
Safety Monitoring Requirements
Dental Evaluation
- All patients must receive dental examination before initiating denosumab 3, 10
- Complete necessary invasive dental procedures before starting therapy 3, 10
- Avoid invasive dental procedures during treatment when possible 10, 6
- Osteonecrosis of the jaw occurs in 1-2% of patients 11, 6
Laboratory Monitoring
- Serum calcium: Monitor throughout therapy, especially first few weeks 1
- Electrolytes, phosphate, magnesium: Monitor regularly 10
- Renal function: No monitoring required for dose adjustment (unlike zoledronic acid) 6, 1
- PTH levels: May increase significantly (200.84% in CKD vs 124.34% in normal function), peaking at 1-3 months 8
Discontinuation Considerations
If denosumab must be discontinued, a dose of zoledronic acid should be administered 6-9 months after the last denosumab dose to prevent rebound bone resorption. 3, 5, 3, 5
This "rebound phenomenon" with multiple vertebral fractures has been reported following denosumab discontinuation 3, 12. The EHA-EMN guidelines specifically recommend bisphosphonate treatment to suppress rebound osteolysis if denosumab is stopped for more than 6 months 5.
Comparative Efficacy
Denosumab demonstrated superiority over zoledronic acid in breast cancer patients, delaying time to first skeletal-related event by 18% (HR 0.82; 95% CI 0.71-0.95; P=0.01) 2, 13. In other solid tumors and multiple myeloma, denosumab was noninferior to zoledronic acid 14. The NCCN guidelines designate denosumab as "category 1, preferred" for castration-resistant prostate cancer with bone metastases 11.